Interleukin-1β induced vascular permeability is dependent on induction of endothelial Tissue Factor (TF) activity by Puhlmann, Markus et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Interleukin-1β induced vascular permeability is dependent on 
induction of endothelial Tissue Factor (TF) activity
Markus Puhlmann, David M Weinreich, Jeffrey M Farma, Nancy M Carroll, 
Ewa M Turner and H Richard Alexander Jr*
Address: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA
Email: Markus Puhlmann - markus.puhlmann@verizon.net; David M Weinreich - dmw4@columbia.edu; 
Jeffrey M Farma - j.farma@temple.edu; Nancy M Carroll - carrollnm@upmc.edu; Ewa M Turner - ewa_turner@nih.gov; H 
Richard Alexander* - richard_alexander@nih.gov
* Corresponding author    
videomicroscopyinflammationneovasculatureendothelial tissue
Abstract
IL-1β is a pleotropic cytokine that may mediate increased procoagulant activity and permeability in
endothelial tissue during inflammatory conditions. The procoagulant effects of IL-1β are mediated
through induction of tissue factor (TF) but its alterations on vascular permeability are not well
characterized. We found that IL-1β induced a rapid and dose-dependent increase in TF activity in
human umbilical vein endothelial cells (ECs) under routine culture conditions. However, IL-1β
caused a rapid and marked increase in permeability across confluent EC monolayers using a two-
compartment in vitro model only in the presence of factor VIII-deficient plasma that was completely
abrogated by neutralizing anti-TF antibody pre-treatment. In vitro permeability was associated with
loss of EC surface expression of VE-cadherin and contraction of F-actin cytoskeletal elements that
resulted in EC intercellular gap formation. These data demonstrate that IL-1β induces marked
changes in permeability across activated endothelium via a TF dependent mechanism and suggest
that modulation of TF activity may represent a strategy to treat various acute and chronic
inflammatory conditions mediated by this cytokine.
Introduction
IL-1β is a pleotropic 17.5 kD cytokine, secreted primarily
by monocytes and macrophages, that mediates the patho-
physiology of various acute and chronic inflammatory
conditions. High levels of circulating IL-1 have been iden-
tified in experimental models of endotoxic shock and
acute bacterial infection and increased gene expression of
IL-1 has been identified in tissues at sites of experimen-
tally induced inflammation [1,2]. Clinically, high levels of
circulating IL-1 have been identified in patients with acute
bacterial infections and elevated levels of IL-1 have been
detected in the diseased articular tissues of patients with
chronic rheumatoid arthritis [3,4]. In experimental mod-
els of endotoxin or E. coli induced shock, immune com-
plex colitis, cancer progression, cachexia, and non-specific
inflammation, IL-1 blockade significantly ameliorates the
pathophysiological host response in these conditions [5-
9]. Of note, administration of recombinant IL-1ra is used
clinically to ameliorate the symptoms of severe rheuma-
toid arthritis [10].
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Although IL-1 receptors are widely expressed on different
cell types, the protein appears to exert many of its physio-
logical actions through effects on endothelial tissue. IL-1
induces endothelial cell (EC) production of cytokines
such as IL-8, IL-6 and TNF, multiple cytokine receptors,
adhesion molecules, growth factors, matrix metalloprotei-
nases, and coagulation factors such as tissue factor, fibrin-
ogen, urokinase plasminogen activator, type 1,2
plasminogen activator and protease nexin 1 [11-14].
Two sentinel homeostatic functions of vasculature are ini-
tiation of coagulation via the extrinsic clotting cascade
and regulation of vascular permeability. Increased vascu-
lar permeability most likely represents the initial event in
pathological or reparative inflammation or angiogenesis
by allowing efflux of plasma proteins into interstitium to
serve as a provisional matrix for circulating inflammatory
cells or activated endothelium [15]. IL-1 is known to
induce a procoagulant phenotype on endothelial tissue
primarily through induction of TF [16,17] and has been
shown to alter endothelial cell monolayer permeability in
in vitro models [18,19]. However, its effects on vascular
permeability  in vivo have not been consistent and the
mechanisms for these effects are not known [20-22]. For
example, in lapine models, systemic recombinant IL-1 has
been shown to induce shock and significant pulmonary
vascular injury manifested by marked perivascular pulmo-
nary edema [20,23]. However, in rodent or guinea pig
models others have not demonstrated any independent
effects of aerosolized or systemically administered IL-1 on
pulmonary vascular permeability or injury [21,22].
The present studies were performed to characterize the
inflammatory properties of IL-1 as mediated by altera-
tions in permeability across endothelial monolayers in
vitro. The data indicate that IL-1 induces both procoagu-
lant effects and permeability via a single TF dependent
mechanism and suggest that TF may represent a novel tar-
get for acute or chronic inflammatory conditions medi-
ated by IL-1.
Materials and methods
Cell culture
Human umbilical vein ECs (hUVECs) were obtained from
Clonetics (Clonetics #CC 2519) and propagated at 37°C
in a 5% CO2 incubator in EGM-2 media (Clonetics #CC-
3156 and #CC-4176) according to the manufacturer's
instructions but without addition of the VEGF-supple-
ment. Cells in the experiments were passaged for a maxi-
mum of 5 generations. MC-38, a non-metastatic
methylcholanthrene-induced murine adenocarcinoma
was maintained in Dulbecco's modified Eagle's medium
(DMEM) (Biofluids, Rockville, MD) supplemented with
10% heat-inactivated fetal calf serum, 2 mM glutamine
and 50 U/mL penicillin/streptomycin.
In vitro permeability assay
In-vitro permeability was quantitated by spectrophoto-
metric measurement of Evans Blue-bound albumin across
Increase in endothelial surface TF activity in response to IL- 1β and dependence of IL-1β induced vascular permeability on  tissue factor expression Figure 1
Increase in endothelial surface TF activity in response to IL-
1β and dependence of IL-1β induced vascular permeability on 
tissue factor expression. Confluent EC monolayers were 
incubated for 3 hours with increasing concentrations of IL-1β 
and a single step coagulation assay performed to measure TF 
activity. A rapid increase of TF activity was observed at IL-1β 
of 100 pg/ml to rapidly plateau at 1 ng/ml or above (a). At 
concentrations of 0.1 ng and 1.0 ng/ ml, IL-1β strongly 
induced vascular permeability only in the presence of Factor 
VIII-deficient plasma and there was a modest increase in vas-
cular permeability without plasma (b). All experiments were 
conducted in triplicate.Journal of Translational Medicine 2005, 3:37 http://www.translational-medicine.com/content/3/1/37
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functional hUVEC monolayers using a modified 2-com-
partment chamber model as previously described in
detail.  Briefly, hUVECs were plated (8 × 105/ well) in 1
µm PET Transwell filter inserts (Falcon #35 3102) using
EGM-2 (as described above). On day 3, cells were washed
and treated with EBM-2 (Clonetics #CC-3156) with 2%
BSA with or without IL-1β with various concentrations as
indicated. Except during time course experiments,
cytokine exposure was kept constant at 2 hours (at 37°C,
5% CO2). Cells were briefly washed with PBS/ Ca2+ and
Mg2+. Fresh EBM-2 including 1% Factor VIII-deficient
plasma (George-King Biochemical) (where indicated) was
added and incubated for an additional 1 hour at 37°C,
5% CO2. In experiments evaluating TF-blocking antibod-
ies, designated wells were incubated first with a 1:100
dilution of antibody (American Diagnostica, #4509) and
PBS/1% BSA. Inserts were washed with PBS/ Ca2+ and
Mg2+ before adding 1.5 mL of Evans Blue (EB) bound to
0.1% BSA in PBS in the upper chamber. Two mL PBS/
Ca2+ and Mg2+ was added to the lower chamber in which
absorbance of EB was determined after 1 hr using a spec-
trophotometer (620 nm). Experiments were performed in
triplicates and repeated multiple times.
Tissue factor assay
Tissue factor activity was determined using a 1-stage coag-
ulation assay. HUVECs were plated (8 × 105/ well) in a 6-
well plate and incubated for 3 days. Cells were washed
with PBS and treated with various concentrations of IL-1β
(in EBM-2/ 2% BSA) for 2 hours at 37°C, 5% CO2. After
this incubation, HUVECs were washed with sterile PBS
followed by incubation for 10 min at 37°C in 1 ml TRIS
(25 mM, pH 8). Plates were transferred to a freezer (-
80°C) for at least 1 hour. After thawing the plates at 37°C,
cells were harvested using a mechanical cell scraper and
centrifuged in an Eppendorf table centrifuge at 14,000
rpm for 5 min. Cell pellets were suspended in 120 µL of
assay buffer (25 mM TRIS/ PBS/0.1% BSA) and immedi-
ately assayed.
Tissue factor activity was measured using a 1-step coagula-
tion assay (Amelung microcoagulation analyzer) by addi-
tion of 100 µL factor VIII-deficient human plasma
(George-King Biomedical). Clotting time was determined
at 37°C and measurement started after addition of 100 µL
of 30 nM CaCl2 (Sigma). The reference curve for TF was
obtained by reconstituting various concentrations of lipi-
dated recombinant hTF (American Diagnostica, # 4500 L/
B2) according to the manufacturer's recommendation and
allowed for detection limits between 0.395 ng/mL to 25
ng/mL (7 – 470 pM/mL).
Immunohistochemistry
HUVECs were grown to confluence on fibronectin coated
two well culture slides (BIOCOAT Fibronectin, Becton
Dose dependent increase in EC monolayer permeability by  1L-1β Figure 2
Dose dependent increase in EC monolayer permeability by 
1L-1β. ECs were exposed to increasing concentrations of 
cytokine as described. All experiments were done in the 
presence of factor VIII deficient plasma.
After stimulation of EC monolayers with 0.1 or 1.0 ng/ mL,  IL-1β, cells were incubated with or without blocking TF-anti- bodies before addition of Factor VIII-deficient plasma Figure 3
After stimulation of EC monolayers with 0.1 or 1.0 ng/ mL, 
IL-1β, cells were incubated with or without blocking TF-anti-
bodies before addition of Factor VIII-deficient plasma. While 
permeability increased substantially in the absence of TF-
blocking antibodies it could be complete abrogated by block-
ing TF receptors (c) demonstrating the necessity of endothe-
lial TF activity and activation of the extrinsic coagulation 
cascade to induce permeability. Results were conducted in 
triplicate.Journal of Translational Medicine 2005, 3:37 http://www.translational-medicine.com/content/3/1/37
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Dickinson, # 354628) and exposed to IL-1 as described
for the permeability assays. After fixation with 4% formal-
dehyde (RT, 10 min), cells were permeabilized with 1%
Triton X for 10 min. A 1:200 dilution of a polyclonal VE-
cadherin antibody (Santa Cruz Biotechnology, #sc-6458)
was used as primary antibody and incubated at RT for 1
hour. After several washes with PBS, cells were labeled
with Alexa Fluor 488 donkey anti-goat IgG (Molecular
Probes, #A-11055) for 1 hour at RT. After repeated
washes, the F-actin cytoskeleton was stained with Texas
Red labeled phalloidin (Molecular Probes, #T-7471) for
40 min at room temperature. Slides were mounted and
sealed using Gel/Mount (Biomeda, #M01). Photomicro-
graphs were obtained with a Zeiss Axiovert 200 M inverted
fluorescent microscope (Zeiss, Germany) at 400 ×
magnification.
Results
TF induction and permeability in endothelial cells by IL-1β 
in vitro
TF induction in ECs was assessed under basal culture con-
ditions using a single-stage coagulation assay after a 2-
hour exposure to various concentrations of IL-1β. At con-
centrations of 100 pg/mL and higher, TF activity was
markedly increased (Figure 1a). There was little TF activity
measured at concentrations of IL-1β below 100 pg/mL
and no further increase in TF activity was observed above
1 ng/ml. The effects of IL-1β on in vitro vascular permea-
bility were assessed using a two-compartment model as
Effect on IL-1β on intercellular VE-cadherin complexes on ECs is shown Figure 4
Effect on IL-1β on intercellular VE-cadherin complexes on ECs is shown. ECs were grown to confluence on fibronectin coated 
glass slides. Cells were stained for VE-cadherin and F-actin and visualized using an inverted fluorescence microscope. Untreated 
ECs form a functional monolayer without cellular gaps (control). Fluorescein labeled VE-cadherin antibodies demarcated indi-
vidual cell borders whereas a Texas Red F-actin antibodies illustrate a relaxed cytoskeleton. Factor VIII-deficient plasma or IL-
1 treatment alone showed similar staining patterns as untreated control cells. However, when used in combination there were 
large intracellular gaps seen (white arrows) in association with downregulation of VE-cadherin and the F-actin cytoskeletal fila-
ments appear contracted and aligned in a spindle fashion.Journal of Translational Medicine 2005, 3:37 http://www.translational-medicine.com/content/3/1/37
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Schematic of proposed mechanism of IL-1 induced vascular permeability Figure 5
Schematic of proposed mechanism of IL-1 induced vascular permeability. Local IL-1 production results in tissue factor upregu-
lation on EC's. In the presence of extrinsic clotting cascade factors local thrombin production activates the EC thrombin recep-
tor and results in VE-cadherin disassembly and contraction of cellular F-actin elements. The resulting intercellular gap 
formation allows efflux of plasma, proteins, and inflammatory cells into the interstitium.Journal of Translational Medicine 2005, 3:37 http://www.translational-medicine.com/content/3/1/37
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described. There was only a slight increase in permeability
above background (PBS control) after a 2-hour exposure
to 0.1 or 1.0 ng/mL of IL-1β under basal culture condi-
tions and exposure of ECs to factor VIII-deficient plasma
alone had no effect on permeability (Figure 1b). However,
at IL-1 doses that resulted in increased TF activity, IL-1 β
caused a marked increase in permeability in the presence
of factor VIII-deficient plasma (Figure 1b). Figure 2 shows
a dose-dependent increase in EC permeability after a 2-
hour incubation with IL-1β in the presence of factor VIII-
deficient plasma. Permeability increased after only a 15-
minute exposure to IL-1β compared to PBS control treated
ECs and continued to increase with longer incubation
times up to 90 minutes. However, incubation times of 2
hours or longer did not result in further increases in per-
meability (data not shown).
To test whether TF induction on ECs was responsible for
the alterations in permeability by IL-1 β, experiments
using pre-treatment with a neutralizing anti-TF antibody
were performed. Anti-TF antibody had no independent
effect on permeability. However, IL-1β induced flux of
Evans Blue-bound albumin across EC monolayers was
completely abrogated in the presence of TF antibody (Fig-
ure 3). Together, these data demonstrated that IL-1β
induces a rapid, dose dependent increase in permeability
across EC monolayers via a TF dependent mechanism.
Activation of the extrinsic coagulation cascade by IL-1β 
leads to conformational changes of the EC cytoskeleton 
and loss of VE-cadherin complexes
To characterize the EC morphological changes that occur
with IL-1β induced permeability we performed immuno-
histochemistry studies on ECs under conditions that
resulted in increased permeability in-vitro. Figure 4 illus-
trates the effects of IL-1β on VE-cadherin, the major inter-
cellular EC adhesion molecule, and F-actin cytoskeletal
staining on EC monolayers. Untreated control confluent
EC monolayers had homogenous VE-cadherin staining
along cellular junctions with diffuse unorganized
cytosolic F-actin and abundant localization adjacent to
cell membranes. In the presence of factor VIII-deficient
plasma alone or IL-1β alone, the EC monolayers remained
intact with uniform well established intercellular tight
junctions reflected by VE-cadherin and F-actin staining
comparable to untreated cells. Incubation of EC monolay-
ers with IL-1β and factor VIII-deficient plasma demon-
strated markedly diminished VE-cadherin staining and
associated F-actin cytoskeletal alignment particularly in
areas of intercellular gap formation (Figure 4 arrows).
Discussion
IL-1β exerts many of its proinflammatory effects through
modulation of vascular permeability. Our data indicate
that induction of tissue factor on the surface of ECs plays
a central role in the regulation of vascular permeability by
IL-1. Exposed endothelial surface TF, in the presence of
plasma, forms complexes with coagulation factor VIIa and
activates the extrinsic coagulation cascade. Local
thrombin production most likely results in EC intercellu-
lar gap formation associated with decreased VE-cadherin
and contraction of cytosolic F-actin fibers. We noted that
in the absence of coagulation factors, IL-1β induces negli-
gible permeability and that in the presence of factor VIII-
deficient plasma, neutralizing TF antibodies completely
abrogated IL-1 induced permeability. Taken together,
these data indicate that IL-1 induction of TF on ECs repre-
sents a common initiating cellular event that results in
both a procoagulant and permeable phenotype. Produc-
tion of IL-1 at sites of acute or chronic inflammation may
result in local alterations in vascular permeability medi-
ated through the TF pathway and, to that end, modulation
of TF activity may be a useful strategy to control the host
inflammatory response (Figure 5).
We have previously shown that TNF shares these proper-
ties in an in vitro system highlighting the know widely
overlapping biological activities of these two cytokines
[24,25] particularly on endothelial tissue [26]. The acute
loss of VE-cadherin complexes, contraction of F-actin
cytoskeletal fibers, and the formation of large intercellular
gaps due to TNF or IL-1 indicates that these morphologi-
cal alterations are secondary to physiological EC
responses rather than non-specific cell injury. EC monol-
ayer integrity in this model is restored after the inflamma-
tory stimuli is removed [27]. The effects are only observed
in the presence of plasma, and hence, with activation of
the extrinsic coagulation cascade and thrombin
production.
It is interesting that the selective procoagulant and perme-
ability effects of TNF, a cytokine with broadly overlapping
biological activities with IL-1, on tumor neovasculature
have been applied in the clinical treatment of cancer.
When high dose TNF is administered via an isolated organ
perfusion there is increased local permeability followed
by selective obliteration of the neovasculature [28]. These
selective effects on tumor neovasculature are thought to
be important in augmenting delivery of chemotherapy,
such as melphalan, to the tumor bed [29]. Our data would
suggest that IL-1 might be a suitable alternative to TNF in
this capacity because of the similar vascular effects and its
limited toxicity compared to the other.
In summary, these experiments demonstrate that IL-1
mediates potent permeability effects on endothelial tissue
that is mediated through EC surface expression of TF. To
that end, TF activity may represent a novel target to
ameliorate pathological inflammatory conditions medi-
ated by this cytokine.Publish with BioMed Central    and   every 
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